2022 年 11 月至 2023 年 5 月期间，65 岁及以上人群接种二价 COVID-19 加强针预防 COVID-19 死亡的效果，澳大利亚。
Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023.
机构信息
National Centre for Immunisation Research and Surveillance, Sydney Australia.
出版信息
Euro Surveill. 2023 Nov;28(47). doi: 10.2807/1560-7917.ES.2023.28.47.2300603.
We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%).
我们随访了 2022 年 11 月至 2023 年 5 月期间年龄≥65 岁的 4081257 名澳大利亚成年人，以了解 COVID-19 特异性死亡率，当时重组 SARS-CoV-2 奥密克戎谱系（主要是 XB 和 XBB）以及 BA.2.75 正在流行。与>180 天前针对原始 SARS-CoV-2 的 COVID-19 加强针相比，8 至 90 天前接种二价（原始/BA.1 或原始/BA.4-5）加强针的 COVID-19 死亡相对疫苗有效性为 66.0%（95%CI：57.6%至 72.2%），而 8 至 90 天前接种单价原始加强针的 COVID-19 死亡相对疫苗有效性为 44.7%（95%CI：23.9%至 59.7%）。
Zotero 插件